C&H Weekly

For the latest in Skin, Science and Beauty

Allergan and the future of Neurotoxins

Allergan the pioneers of BOTOX®, have shown further investment in medical science with their recent investment of a clinical stage biopharmaceutical company developing a topical neurotoxin.

“The acquisition of Anterios bolsters Allergan’s commitment to innovation and maintaining its leadership position in neurotoxin development and commercialization,” said David Nicholson, Executive Vice President and President, Global Brands Research & Development at Allergan.

Read the full story here.

Book An Appointment